Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?

Panelists discuss how to approach patients who show inadequate response to initial erythropoiesis-stimulating agent (ESA) therapy, including assessment strategies and potential next steps in treatment modification.

EP: 1.COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial

EP: 2.MEDALIST and IMerge Trial Presentation and Discussion

EP: 3.Debate: Do We Treat First With ESAs or With Luspatercept?

EP: 4.Do We Start Luspatercept at the Highest Dose and Titrate Down or Start Low and Titrate Up?

Now Viewing

EP: 5.Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?

Recent Videos